rosiglitazone has been researched along with lobeglitazone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bahia, MS; Chadha, N; Kaur, M; Silakari, O | 1 |
| Chung, SJ; Hwang, IC; Kim, CY; Kim, DD; Lee, JH; Shim, CK; Woo, YA | 1 |
1 review(s) available for rosiglitazone and lobeglitazone
| Article | Year |
|---|---|
Thiazolidine-2,4-dione derivatives: programmed chemical weapons for key protein targets of various pathological conditions.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Antidiuretic Agents; Antineoplastic Agents; Antioxidants; Drug Design; Humans; Molecular Targeted Therapy; Structure-Activity Relationship; Thiazolidinediones | 2015 |
1 other study(ies) available for rosiglitazone and lobeglitazone
| Article | Year |
|---|---|
Quantification of CKD-501, lobeglitazone, in rat plasma using a liquid-chromatography/tandem mass spectrometry method and its applications to pharmacokinetic studies.
Topics: Administration, Oral; Animals; Calibration; Chemistry, Pharmaceutical; Chromatography, Liquid; Dose-Response Relationship, Drug; Drug Stability; Female; PPAR alpha; Pyrimidines; Quality Control; Rats; Rats, Sprague-Dawley; Reference Standards; Reproducibility of Results; Rosiglitazone; Tandem Mass Spectrometry; Thiazolidinediones | 2009 |